Professional Documents
Culture Documents
The Bioprinting Roadmap
The Bioprinting Roadmap
The Bioprinting Roadmap
View the article online for updates and enhancements. - 3D bioprinting of molecularly engineered
PEG-based hydrogels utilizing gelatin
fragments
Susanna Piluso, Gözde Akdeniz
Skvortsov, Mine Altunbek et al.
ROADMAP
Keywords: biofabrication, bioprinting, cell printing, in vitro biological models, disease models, organoids, organ-on-a-chip
Abstract
This bioprinting roadmap features salient advances in selected applications of the technique and
highlights the status of current developments and challenges, as well as envisioned advances in science
and technology, to address the challenges to the young and evolving technique. The topics covered in
this roadmap encompass the broad spectrum of bioprinting; from cell expansion and novel bioink
development to cell/stem cell printing, from organoid-based tissue organization to bioprinting of
human-scale tissue structures, and from building cell/tissue/organ-on-a-chip to biomanufacturing
of multicellular engineered living systems. The emerging application of printing-in-space and an
overview of bioprinting technologies are also included in this roadmap. Due to the rapid pace of
methodological advancements in bioprinting techniques and wide-ranging applications, the direction
in which the field should advance is not immediately clear. This bioprinting roadmap addresses this
unmet need by providing a comprehensivesummary and recommendations useful to experienced
researchers and newcomers to the field.
2
Biofabrication 12 (2020) 022002 W Sun et al
Contents
1. Introduction 4
2. From cell expansion to 3D cell printing 6
3. Bioinks for 3D bioprinting 8
4. Bioprinting of stem cells 11
5. Large-scale and efficient production of organoids or cell aggregates 13
6. Strategy for bioprinting of tissue vascular system and tissue assembly 15
7. 3D-printed biohybrid tissues as in vitro biological models for disease study 17
8. 3D bioprinting for organ-on-a-chip development 20
9. Biomanufacturing of multicellular engineered living systems 23
10. Bioprinting in space: pioneering new frontiers 25
11. Bioprinting technologies 28
3
Biofabrication 12 (2020) 022002 W Sun et al
4
Biofabrication 12 (2020) 022002 W Sun et al
vascularization and innervation without preformed the field should advance is still evolving. The bio-
or newly formed structures for vasculature and/or printing roadmap aims to address this unmet need
critical functions. Due to the rapid pace of methodo- by providing a comprehensivesummary and recom-
logical advancements in bioprinting techniques and mendations useful to experienced researchers and
wide-ranging applications, the direction in which newcomers to the field.
5
Biofabrication 12 (2020) 022002 W Sun et al
2. From cell expansion to 3D cell printing from one step to the next is critical for addressing the
quality of biofabricated products.
Binil Starly and Edward P Fitts
Department of Industrial and Systems Engineering, • Tissue products that result from biofabrication are
Comparative Medicine Institute, North Carolina State dependent on the growth of adherent cells. Most
University, Raleigh, NC 27695 adherent cells used as the key ingredient in cell
bioprinters are derived from passaging through
2.1. Status. A key component of any biofabrication standard or cell-stack-based flat culture plates [6].
process is the living cells, often required in the 10 These are inherently 2D forms of culture which will
million–20 million cells per ml quantities, with the require substantial amounts of floor space to grow
need to reach cell densities greater than 200 million the necessary therapeutic amounts. This translates
cells for any potent post-biofabricated tissue or to expensive good manufacturing practice (GMP)
organoid structure. Yet, the majority of laboratory- facilities leading to very expensive cell and regen-
based processes for generating these cells are erative medicine therapy procedures.
dependent on flat culture plate solutions to generate
• Current commercially available bioreactors fall
the millions of cells needed to bioprint tissue.
short of being able to adequately monitor the
Biofabrication systems are generally considered a mid- cellular conditions for expanding cell populations
stream operational step in a process that begins from in situ and in real-time. A key technical hurdle is
the tissue biopsy until the last step of delivery of the the ‘black-box’ nature of available bioreactor
product to the patient [1]. Cell expansion is a critical systems for automated cell expansion. Operators
upstream process step for cell and tissue of bioreactor systems during a three week to four
manufacturing. Bioreactor-based systems to expand week expansion phase have limited information
cells for both autologous and allogeneic-based rich in-process data on the status of the expanding
therapies are being considered to replace the time- cells until they are brought out of the chamber for
consuming step of producing enough cells. Further offline sample analysis. Current methods resort to
improvement in bioreactor-based cell-expansion frequent media sampling which are prone to error
systems is required to lower barriers to the adoption of and can get prohibitively expensive in autologous
bioprinting in regenerative medicine and tissue cell-expansion culture.
engineering product markets.
Many of the bioreactor systems currently in use • Variability in characteristics of the incoming cell
today are derived from those that have been in use for population can necessitate changes to the expansion
the biopharmaceutical-based production of vaccines, phase of the culture [7, 8]. A standard operating
viral vectors, and monoclonal antibodies [2]. How- procedure may not always work optimally for
ever, the design of these bioreactors has not considered expanding patient-specific cells. Experienced techni-
the fact that for biofabrication, the cells are the living cians are required to adjust culture conditions within
product. When cells are the product of the cell- regulated limits for optimal output. This can add to
expansion system, critical care must be taken during cost, time and potential loss of quality.
the expansion process to preserve the cellular proper- • A general lack of understanding exists on the effect
ties required for needed functionality in the biofabri- of the various processing conditions on the end
cated product. While the science of cell expansion and quality profile of the cells prior to loading within
design of tissue systems have progressed over the last bioprinters. Several phase I clinical trials are being
two decades, the manufacturing science of the process conducted with the use of therapeutic cells/tissues.
to ‘scale-up’ and ‘scale-out’ to cost-effectively manu- With many of them having the potential to move to
facture these products has not received significant phase II trials and beyond, it is critical to understand
attention and remains a key barrier to market readi- and standardize upstream and downstream proces-
ness [3]. Progress has been made towards cell-expan- sing steps that affect the potency of tissue products.
sion reactors that address the low wall shear
requirement of mesenchymal stem cell (MSC) expan- 2.3. Advances in science and technology to meet
sion, albeit towards ‘scaling-up’ the number of cells challenges. Several new technology platforms can
[4, 5]. More work is to be carried out towards enable solutions to the challenges above. From a basic
automating workflows during a scale-out operation manufacturing science perspective, new studies must
when patient-derived cells from multiple patients are be conducted to understand changes in the cellular
expanded simultaneously for economically viable machinery as the expansion process takes place and
production. how each population doubling affects cellular
potency. Further, tissue-based therapies that involve
2.2. Current and future challenges. As biofabrication the use of patient-specific cells, how the variation in
progresses towards translational research, a holistic cellular profile after the expansion process affects the
view of how the cellular and tissue product transforms biofabricated product must also be understood.
6
Biofabrication 12 (2020) 022002 W Sun et al
Several related technology platforms can be utilized to expansion and biofabricated systems can be very
help meet these challenges. expensive and distributed across various labora-
tories, start-up companies, and large companies.
• New culture platforms must be integrated within Academia across the world can lead the way to
cell-expansion bioreactors to improve the cellular interconnecting hardware systems through a
yield per unit volume. This is possible through global cyber-infrastructure that allows data-shar-
improving the culture surface area utilizing 3D ing and management to lower the barriers for
surfaces, new bioreactor designs specific to auto- those involved in developing new hardware and
logous and allogeneic therapy, culture media that software-based regenerative medicine products.
enhances cellular growth rates, etc. Improving
cellular yield will drive higher efficiency through 2.4. Concluding remarks. The science behind the
which cells are produced for the biofabrication scale-up and scale-out of cell manufacturing and
market and improve scale-out operations. tissue biofabrication is critical to the adoption of these
• Cell-expansion bioreactors are complex hydro- processes in therapeutic and non-therapeutic
dynamic environments with a complex multi- applications. Mass production of tissue/organoids for
physics environment, involve chemical kinetics, allogenic therapy or non-therapeutic applications will
flow-induced reaction, and a living cellular mat- require cell-expansion systems that produce massive
erial expanding under the right conditions. New quantities of cellular products, with processes moving
hardware systems to determine cell number, away from labor-intensive processes to production
viable cell mass, cellular status (for example, scale methods. For autologous therapy of personalized
undifferentiated or differentiated) in real-time biofabrication products, new challenges of quality
and in-process without negatively disturbing the control and scale-out production strategies must be
growth rate of the cells can significantly advance devised for economic viability. New cyber-physical
cell-expansion-based operations. Real-time and technology combined with innovative artificial-
label-free sensors are required to quantify key intelligence-based learning algorithms built into
performance indicators (KPI) to allow quality-by- biological machines and advances in materials
design approaches to be implemented for both
development can perhaps address many of the
cell-expansion reactors and associated biofabri-
technical challenges posed by engineered tissue/
cated systems [9, 10].
organoid manufacturing technology.
• New computational models must be developed
that integrate real-time sensing, and control
strategies that adapt to expanding cell populations Acknowledgments
based on cellular characteristics will be critical for The author would like to acknowledge the support of
improving the robustness of the manufacturing US NSF Grant# US NSF #1562139 and funds from
process. Gathering experimental data from cell the NC State Comparative Medicine Institute.
7
Biofabrication 12 (2020) 022002 W Sun et al
8
Biofabrication 12 (2020) 022002 W Sun et al
Figure 2. Bioinks for extrusion bioprinting. (a) An outline of the traditional biofabrication window for extrusion bioprinting, where
denser hydrogels are required for optimal extrusion characteristics (fabrication window) and softer hydrogels are required to support
biological processes such as cell proliferation, differentiation, and ECM production (cell-culture window). The traditional
biofabrication paradigm has focused on developing hydrogel bioinks with properties in the region between these two windows,
whereas novel bioink strategies are being developed that exist in both the cell-culture and fabrication windows [14]. (b) A schematic of
shear-thinning behaviour during extrusion of a bioink containing reversible crosslinks. (i) In the syringe the polymer chains form a
temporary crosslinked network. (ii) Upon dispensing through a needle the temporary network is broken through shear and the
viscosity is decreased to facilitate flow. (iii) Upon deposition, shear stresses are removed and the reversible crosslinks reform to enable
filament localisation [14]. (c) Representative rheological properties of a shear-thinning bioink showing decreasing viscosity with
increased shear rate, and (d) shear-yielding (G′ and G″ crossover at approximately 85% strain) with increased strain (0 to 1000 %,
1 Hz) (unpublished data, Burdick lab).
Towards the first approach, a number of smart wide range of patterns [20]. These approaches allow
bioprinting strategies have been developed that permit increased complexity within 3D environments.
the controlled extrusion of low-viscosity hydrogels. Advances are also being made in lithography
For example, low-viscosity methacrylated hyaluronic bioprinting, such as the transition to newer photo-
acid (HA) and GelMA bioinks can be extruded as initiators (e.g. transitional metal-based photoinitia-
stable filaments using a transparent nozzle that enables tors) to reduce irradiation intensities and times to
photocrosslinking during extrusion, prior to deposi- speed up printing [15]. When combined with photo-
tion [17]. Another approach for formulating such absorbers to limit off-site curing, such high-resolution
materials into printable bioinks is the addition of a features (<25 μm) can be obtained [15] (figure 3(c)).
sacrificial polymer to stabilise the bioink during In addition to speeding up crosslinking, strategies that
extrusion. For example, alginate has been widely accelerate replenishment of the bioink between suc-
utilized for these purposes as it can be rapidly cross- cessive polymerization steps will also help reduce
linked during extrusion in the presence of calcium and fabrication times. Recently, multibioink lithography
is easily washed out post-printing (figure 3(a)) [18]. approaches have also been developed by integrating a
Another promising approach involves printing microfluidic inlet with a DLP bioprinter that allows
bioinks into granular support hydrogels that fluidize switching of the bioresin during printing to produce
around the printing needle during extrusion and heterogeneous constructs [16] (figure 3(d)).
subsequently solidify to trap the printed structure in
3D space [19]. For example, low-viscosity bioinks such 3.4. Concluding remarks. Advances in bioink
as poly (vinyl alcohol) (PVA), which are challenging to development and processing, ideally addressed
process using traditional layer-by-layer extrusion, can simultaneously in the future, will enable the further
be extruded into complex 3D geometries using development of bioprinting techniques to realize their
granular support baths that provide stabilization of the true potential towards the fabrication of in vitro
printed structure and can later be removed models, or for the development of implantable
(figure 3(b)) [19]. Similarly, shear-thinning hydrogels constructs for tissue repair. Many questions are yet
can be deposited into the 3D space of another unanswered, such as the needed resolution and
hydrogel, including with multiple bioinks across a material complexity to achieve a functional product,
9
Biofabrication 12 (2020) 022002 W Sun et al
Figure 3. Advances in bioinks for extrusion and lithography bioprinting. (a) A schematic demonstrating a widely used coaxial
crosslinking technique, where a low-viscosity alginate/GelMA bioink is included in the core region and calcium chloride solution is
included in the shell region. When the two solutions come into contact at the needle tip the alginate is immediately ionically
crosslinked to stabilise the filament. Next, the GelMA bioink is covalently crosslinked with UV light, and the alginate component is
then washed out using a mild chelating agent [18]. (b) A schematic outlining extrusion of a bioink into a granular support material
composed of Carbopol microparticles (0.2 μm) that locally fluidize around the printing nozzle during writing to trap the printed
filament within 3D space, and an example of a printed thin-shell octopus model printed using the technique [19]. (c) High-resolution
DLP photolithography of solid pyramid, cone, and flower structures with feature sizes of 50–500 μm through improved bioink
formulation. The bioink is composed of methacrylated poly (vinyl alcohol) (PVA-MA), GelMA, and a RU (tris-bipyridyl- ruthenium
(II) hexahydrate)-SPS (sodium persulfate) photo-initiator [15]. (d) Microfluidic enabled DLP lithography bioprinting of diverse
multimaterial cellular hydrogels with high-resolution features [16].
which will certainly vary for different target tissues and with a reduced time for bioprinting with increased
research questions. For sure, bioinks must not only resolution where needed.
meet the demands of the bioprinting process (e.g.
extrusion, lithography), but they need to provide Acknowledgments
suitable environments for cells. Future advances will The authors would like to acknowledge support from
be needed in our understanding of how the bioink the AO Foundation and the German Research Foun-
controls cell behaviour to actively orchestrate cells dation (DFG; project number 326998133 – TRR 225,
towards correct functional tissue maturation, together subprojects B02 and B04).
10
Biofabrication 12 (2020) 022002 W Sun et al
11
Biofabrication 12 (2020) 022002 W Sun et al
subdivided into scale, quality assurance, and infra- bioprinting, will be essential in realising the potential
structure. Generating microtissues in a research set- basic science and therapeutic applications of stem
ting requires roughly 100 million to 1 billion cells. To cells, allowing production of more tissue‐like
repair solid tissue or organs through bioprinting, structures. As discussed above, the majority of current
10–100 billion or more cells may be required [24]. differentiation culture protocols were designed and
Such an immense increase in scale itself necessitates were optimized for 2D culture. The move to 3D
changes in culture, expansion, and production of culture presents problems that likely require
bioprinted tissue [24, 27, 29]. The use of PSCs also significant alteration of current culture procedures
brings the risk of undifferentiated stem cells generat- due to the increased system complexity which must be
ing a teratoma cancer after implantation to a patient; accounted for. New bioprinting technologies in
therefore, assurances must be made that all stem cells combination with other platforms, such as bioreactors
have sufficiently matured first. Stem cells derived from and organs‐on‐a‐chip, can allow more efficient and
patients have the potential to create autologous tissue cost‐effective cell expansion and differentiation
and organ grafts that would be free from immune compared to standard 2D. As our understanding of
rejection. For this to be a possibility, however, appro- the niche in which stem cells reside grows, so too will
priate facilities would need to exist to: extract; purify; our capabilities in mimicking that niche in vitro using
expand; bioprint; and differentiate stem cells into the biofabrication techniques. Alongside better
desired tissue. All this must also be conducted under understanding and optimization of the mechanical
GMP‐compliant conditions. Currently, such facilities parameters of bioprinting, it is foreseeable that
do not exist at scale, but would be essential for practical
bioprinting could be the platform to utilize human
translation, as well as regulatory approval and possibly
stem cells to produce artificial solid tissues and organs.
oversight.
12
Biofabrication 12 (2020) 022002 W Sun et al
5. Large-scale and efficient production of ECM after their enzymatic isolation. Controlling
organoids or cell aggregates aggregate sizes is difficult, and excess aggregation
through the agglomeration of small organoids causes
Yasuyuki Sakai, Marie Shinohara and Masaki central necrosis or unintentional development/
Nishikawa differentiation. Thus, robust but highly scalable
Department of Chemical Engineering, Graduate School production methods are required to extend the use of
of Engineering, University of Tokyo, Tokyo, Japan organoids.
Another important problem common in both
5.1. Status. Because organoids better mimic microwell-based and suspension culture-based meth-
physiological microstructures of in vivo tissue or ods is the extensive use of expensive growth factors. In
organs where heterogenic cell populations are well in vivo microenvironments, such growth factors are
organized in a hierarchical manner, they are highly produced by stromal cells, and immediately and
expected as advanced microtissue elements for locally act on neighbouring target cells, for example,
implantable tissue and for in vitro cell-based assays, epithelial cells, at very high concentrations often with
including disease models. However, as recently the help of ECMs. Although we may partly expect such
reviewed by Schneebergat et al [31], there are many in vivo-like autonomous mechanisms in organoids,
problems with the practical applications of supplementation of growth factors at high concentra-
organoids, such as large-scale production, control tions out of physiological ranges is usually necessary to
of maturation in vitro, integration of organoids into grow and develop organoids in vitro. As alternatives to
much larger tissues having macro-scale tissue such expensive growth factors, various small mole-
structures, etc. cules with similar biological activities have been
The first important issue to tackle with the use of identified and partly used in differentiation protocols
organoids is their large-scale production. Organoids of iPS/ES cells. However, these chemicals are often
are usually produced in small-scale tissue culture expensive. Ideally, if we reproduce the above-men-
dishes or plates that are not easily scalable. In tioned in vivo autonomous mechanisms in vitro, then,
addition to just scaling-up of the production, the it will definitely lead not only to the enhancement of
reduction of the production costs is another serious physiological relevance but also to the reduction in the
cost for their large-scale production.
problem. This is because many expensive growth
factors are required in a cocktail and have to be
5.3. Advances in science and technology to meet
refreshed at each medium change to organize,
challenges. In cases of microwell-based organoid
induce, and maintain organoids derived from stem
production in static culture, we note its diffusion-
cells such as induced Pluripotent Stem/Embryonic
limited oxygen supply, and that the use of oxygen-
Stem (iPS/ES) cells or tissue progenitors. To address
permeable materials such as polydimethylsiloxane
these issues, we need to integrate basic biological
(PDMS) for the culture substrates removes this
knowledge with various chemical engineering meth-
limitation. This enables cells to take aerobic
odologies, including high cell-density bioreactor
respiration, even at higher inoculum density, leading
culture, as well as advanced microtechnologies, such to remarkably enhanced cell-to-cell organization and
as microfabrication and biofabrication. ECM production (figure 5). Active ECM production is
one of the important keys to the success of heterogenic
5.2. Current and future challenges. Organoid cell organization into one aggregate. Moreover, we
production usually begins with reaggregation of reported that a significant increase in inoculum cell
isolated single cell populations in confined geometry, density was achieved, and that it led to remarkable
such as microwells in static culture (figure 4). This enhancement of per unit area-based productivity of
method is very robust, and we may easily control the organoids or aggregates, while retaining various
sizes of the organoids with a high uniformity. advantages of static microwell cultures (figure 4)
However, it is not readily applicable to larger-scale [32, 33]. In addition, use of oxygen-permeable
production. From the stand point of scalability, materials for direct cellular oxygenation can reduce
aggregate suspension bioreactors are the best way, oxygen concentrations to low physiological ranges
and their applications to iPS cell differentiation while keeping aerobic cellular respiration. This may be
towards cardiac, hepatic, or pancreatic lineages have a very important culture operation to suppress the
been reported. As opposed to the potential possible oxidative stresses to immature or progenitor
advantages of suspension cultures, control of cells, which may not yet have well-developed
organization, induction and biological preservation mechanisms to protect themselves against such
of organoids is much more difficult versus static oxidative stresses.
microwell culture (figure 4). Sometimes initial cell For the success of organoid culture in suspension
aggregation in dynamic conditions does not succeed. (figure 4), beforehand we sometimes use microwell-
Organization of heterogenic cell populations is based methods to organize isolated single cells in
usually difficult, presumably because they have lost microwell static culture, and then transfer them to
13
Biofabrication 12 (2020) 022002 W Sun et al
Figure 4. Current methodologies for efficient production of organoid or cell aggregates; the microwell-based method (a), and the
suspension culture-based method (b).
Figure 5. How to enhance the efficacy of organoid production from the chemical engineering concepts. An advanced microwell
allowing direct oxygenation of cells (a), and incorporation of a dialysis operation in suspension culture (b) for high cell-density
production.
dynamic suspension culture. To control excess aggre- increases. Actually, such a dialysis culture also enabled
gation, some molecules, such as E-cadherin or other iPS cell propagation or their hepatic differentiation at
lipid-bearing proteins in culture medium, were shown very high cell density (over 107 cells cm−3) when we
to inhibit the phenomena [34]. Aggregation of hetero- used some reagent suppressing excess cell aggregation
geneous cells in suspension is usually difficult; there- (to be published elsewhere). This may lead to further
fore, some artificial molecules, such as Eudragit cost reduction of organoid culture in the near future.
(Evonik Nutrition & Care GmbH, Germany), can be
used to overcome the low attachability to each other to 5.4. Concluding remarks. Progress in stem cell
organize them into one aggregate. Such careful control biology and in vitro culture is opening up new doors to
of aggregation or their development may enable robust regenerative medicine and better physiological cell-
and large-scale organoid production with high uni- based assays for disease models. However, to bring
formity, as realized in static microwell methods. these advancements into practice, various chemical
High density culture of aggregates is another engineering methodologies and microtechnologies,
important direction for efficient production of large including biofabrication or microfluidics, have to be
numbers of organoids. Conventional chemical engi- fully utilized. Together with such developments,
neering tells us fed-batch dialysis culture may be the continuous efforts are required to realize better in vivo
ideal culture system [35, 36] (figure 5). Such a system -like microenvironments at different time lengths and
allows an increase in cell density in the cell-culture scales in vitro. Unfortunately, at this moment,
vessel in which growth factors are added, while the allowing further in vitro maturation of organoids is
dialysis operation supplies the cells with enough still a significant biological challenge; progress
nutrients and removes metabolic waste across the remains limited due to insufficient knowledge about
dialysis membranes. This reduces the cost of exogen- tissue development, particularly about in vivo
ous growth factors, and may enable full utilization of mechanisms of autonomy. Careful study on in vivo
paracrine or autocrine factors. In addition, this mechanisms of autonomy is required with the help of
advantage can be further enhanced as the cell density various engineering-based technologies.
14
Biofabrication 12 (2020) 022002 W Sun et al
6. Strategy for bioprinting of tissue vascular shortened time for anastomosis, and delivery of high
system and tissue assembly numbers of cells.
Although numerous biofabrication strategies have
Jinah Jang and Dong-Woo Cho been successfully applied to mimic sophisticated
Pohang University of Science and Technology human tissues, complex and multistep fabrication
processes restrict the hierarchical design for higher-
6.1. Status. The human vascular system is an organ order tissue modelling. In addition, this complicated
system that transports oxygen, carbon dioxide, process increases the time required for construction
nutrients, hormones, and blood cells, and helps and affects the viability and functionality of the printed
maintain body homeostasis. It is also essential for the cells. Thus, modularisation techniques have been
prolonged survival and nourishment of engineered attempted to fabricate human-scale tissue constructs
tissue constructs that are expected to replace the native more appropriately.
human tissues and organs. The lack of control over the Modules (e.g. cell aggregates, laminar cell sheets,
organization of the vasculature makes it difficult for biomolecules) can induce self-assembly by virtue of
organs to function properly. This results in poor cellular sorting or tissue fusion processes, form the
assembly of blood vessels after transplantation, and systemic level, and evolve into the quiescent state,
impedes the integration between the construct and the indicating a structurally and energetically stable state
host. In this respect, strategies capable of [42]. The physical assembly of each module or
recapitulating vascular branching in the organs are polymeric framework as the LEGO® block may
highly desirable for the engineering of large-volume represent an additional solution. However, it usually
tissues. requires delicate assembly processes, resulting in
Cells (e.g. parenchymal, stromal, and supporting operator-related variability and poor tissue morpho-
cells) reside in the surrounding microenvironment genesis. Therefore, cellular/physical assembly per-
that consists of various ECMs, as well as with external formed by computer-assisted fabrication methods is
stimuli and soluble factors, enabling them to perform very much required.
specific functions. For instance, properly positioned
stromal and supporting cells help synthesize and 6.2. Current and future challenges. The intricate
nature of intra- or inter-tissue connections
remodel the ECM, and the secretion of specific
complicates the process of natural tissue formation.
cytokines contributes to the creation of a tissue-
Printing of perfusable channels or blood vessel
specific microenvironment. Therefore, proper biofab-
analogues has enabled us to recapitulate the tube-like
rication strategies can facilitate the pre-positioning of
structure of endothelial cells and exploit their ability to
cells at the desired locations, inducing self-assembly of
spontaneously form a lumen by supporting the niche
tissue architecture and supporting tissue mimicry.
microenvironment [41]. Along with the spatial pre-
A multicellular 3D bioprinting approach for
positioning of cells and the use of bioinks, the
vascularization is emerging as a highly promising
application of external stimuli (e.g. shear/cyclic stress,
strategy [37]. It enables the embedding of perfusable
pulsatile force) may represent an additional factor for
channels, as well as the spatial positioning of vascular
enhancing tissue maturation [43, 44]. In particular,
cells (e.g. endothelial progenitor cells (EPCs), human shear stress is crucial for the secretion of growth
umbilical vein endothelial cells (HUVECs), induced factors (e.g. platelet-derived growth factor and
pluripotent stem-cell-derived endothelial cells (iPSC- transforming growth factor-beta 1) and the activation
ECs), and smooth muscle cells) in the engineered of the associated molecular signals leading to ECM
construct. For 3D printing of an intravascular net- deposition (e.g. collagen, elastin). However, the
work, the size of the vasculature is usually less than creation of the physical connection between the
500 μm, close to the microvasculature range structure and the circulation system (e.g. syringe
(50–500 μm). The distance between the tissue and the pump, peristaltic pump) is a critical issue. In addition,
vessel should be around 100–200 μm and is a critical the end-to-end anastomosis between the structure and
issue: a distance larger than 200 μm could impede the native vessel is a remarkably tricky process.
blood circulation or molecular diffusion in the engi- The tissue-specific microenvironment, specifically
neered tissues after transplantation. the surrounding matrix, can biochemically induce
To achieve such specific design criteria, many tissue morphogenesis. Recent studies applying tissue-
strategies have been attempted: (1) micropatterning of specific ECM-based bioink (e.g. decellularized ECM
vascular cells for inducing tissue assembly [38, 39], (2) derived from fat, cartilage, heart, liver [38, 45, 46])
sacrificial channel fabrication and moulding [40], (3) showed a striking enhancement of numerous biologi-
direct printing of perfusable vessel-like structures [41], cal processes in embedded cells, including cell pro-
and (4) patterning of perfusable structures with liferation, differentiation, angiogenesis, and tissue
specific architectures [37]. These recent advancements formation. Although these bioinks have proved the
in biofabrication have shown remarkable abilities to possibility of promoting tissue maturation, technical
facilitate thick and large tissue reconstruction, improvements are required to more tightly control the
15
Biofabrication 12 (2020) 022002 W Sun et al
structural integrity by regulating physicochemical application of these bioinks is required to build tissue
characteristics. constructs. Similarly to cellular-ECM modules,
structural modules (e.g. polymeric scaffolds) can also
6.3. Advances in science and technology to meet be considered as building blocks, indicating that the
challenges. Bioprinting-based modular tissue structural, cellular, ECM, interfacing, and fixation
assembly can facilitate the highly defined and characteristics are critical factors for a higher level of
controllable construction of large-volume tissues. The tissue integration [42].
modules are largely categorised into three types:
cellular, ECM, and structural modules, based on the 6.4. Concluding remarks. Current advances in
simplification of complicated human tissues, and biofabrication have shown remarkable capabilities to
reflect the assembly of these functional units in a layer- recreate human vasculatures and large organs. Various
by-layer approach. Various cellular and ECM attempts have been made to promote modular tissue
modules, such as endothelial and stromal cells (e.g. formation as well as vessel formation, including early
fibroblasts, pericytes, MSCs), cell aggregates, anastomosis between microvessels in the construct,
spheroids, hydrogels (e.g. synthetic, natural, hybrid blood circulation, and tissue maturation after the
biomaterials), and bioinks, a formulation of cells transplantation. Specifically, automated bioprinting
suitable for processing by biofabrication, have been technologies can collectively provide necessary cells,
specifically positioned in the constructs. The design of functions, and microenvironmental cues for achieving
the modular assembly varies depending on the large-volume tissue construction. Although the
vascularization strategy (e.g. sprouting-, self- challenges facing this strategy are immense,
assembly-, sacrificial channel-based approaches) and achievements may lead to clinical applications for
the geometry of vessels (e.g. branching angle, providing advanced therapeutic methods,
branching frequency, tortuosity). In addition, understanding disease mechanisms, and engineering
advanced bioinks enable rapid lumen formation by
of microtissue models.
providing tissue favourable binding sites to the
endothelial cells. Various approaches, including
vascular tissue-derived ECM bioink and coaxial Acknowledgments
nozzle-based printing [41], and photodegradable This research was supported by the National
materials containing the integrin-binding RGDS Research Foundation of Korea (NRF) grant (No.
peptide sequence (H-Arg-Gly-Asp-Ser-OH) with the 2019R1A3A3005437, 2015R1A6A3A04059015), and
projection-based microstereolithography technique the ‘ICT Consilience Creative Program’ (IITP-R0346-
have been explored for direct lumen formation and 16-1007) supervised by the IITP (Institute for Infor-
endothelialisation [40]. Further examination and mation & Communications Technology Promotion).
16
Biofabrication 12 (2020) 022002 W Sun et al
7. 3D-printed biohybrid tissues as in vitro the skin into the bloodstream.To fulfill such require-
biological models for disease study ments, in vitro reconstructed skin equivalents shall be
composed of a well-differentiated epidermis, an epi-
Minghao Nie and Shoji Takeuchi dermis–-dermis barrier with a firmly deposited basal
The University of Tokyo membrane, fibroblast-populated dermis, and an
endothelial barrier consisting of a layer of endothelial
7.1. Status. In vitro reconstructed tissues need cells with tight junctions. Current technology for the
precisely controlled 3D arrangements of cells and fabrication of a skin equivalent benefits from the
ECMs to correctly predict drug responses for disease contraction of a fibroblast-populated collagen lattice
study. By blending 3D printing with the technical (FPCL) [48]. Based on such techniques, keratinocytes
know-how of biomaterial handling from the field of can be subsequently seeded on top of the contracted
tissue engineering, 3D bioprinting holds the potential FPCL to form an epidermis layer. However, current
to create better disease models by enabling rapid technology has not achieved the incorporation of
fabrication of tissues with accurate spatial capillary vessels into the FPCL; FPCL contraction leads
arrangement of cells [47]. to the collapse of perfusable lumens and the detach-
Within decades of development, bioprinting has ment of FPCLs to the injection needles/nozzles. For
transformed itself from science fiction to reality by the reconstruction of skin equivalents with well-
breaking through two major hurdles: cell-viability established transdermal barrier functions, techniques
loss, and the inability to scale-up. First, cells suffer that can support the stable perfusion of FPCLs are
viability loss since printing conditions are not always strongly required.
optimal for cell survival; the shear forces necessary for Second, the large force-to-displacement transduc-
the ejection of cells/ECM, as well as pH/temperature tion function is the trademark of skeletal muscle/
change during printing, will cause damage to cell cardiac tissue. Analyzing the displacement actuation
membranes, and therefore leads to cell death. To provides the opportunity to directly visualize scoring
maintain cell viability, optimized biomaterials and on the force generated by skeletal muscle in response
printing conditions have been determined for various to drugs. Even though tiny muscle tissues with highly
aligned actin filaments have been fabricated in vitro,
printing modalities, such as inkjet-based and
the contractile motion of these fabricated tissues is
extrusion-based. Biomaterials, which can buffer
generally small since they lack the incorporation of
pH change and rapidly crosslink during printing, have
tendon/skeletal parts, which have the potential to
been developed to incorporate cells.Improved
amplify their motion. To establish the large force-to-
post-printing cell viability is achieved by optimizing
displacement transduction function of skeletal mus-
thedesignsof the printheads to reduceprinting shear
cle/cardiac tissues, techniques such as 3D printing/
stress,andsterilebioprinter housings to prevent con-
bioprinting may allow firm assembly of muscle tissues
tamination. Second, with the prevalence of extrusion-
with cantilever/joint-type skeletal/tendon constructs.
based printing methods, the rapid fabrication of
In addition, the incorporation of neuron-muscular-
millimeter-scale constructs with precise 3D spatial junctionsinto the muscle tissue is also important since
arrangements of cells has been made possible. These it allows the modelling of neuron-related muscle
capabilities have drastically boosted clinical R&D by disease.
shortening the sample preparation time for drug
screening. 7.3. Advances in science and technology to meet
challenges. We believe that 3D-printed biohybrid
7.2. Current and future challenges. Despite current tissues, which combine 3D-printed non-living parts
achievements enabling rapid printing of cell-laden (such as polymers/electrodes) with biofabricated/
hydrogel constructs with high cell viability, many bioprinted cellular parts, could potentially solve the
functions that are the hallmarks of in vivo tissue are above-mentioned challenges.These biohybrid tissues
not yet successfully replicated. These functions are take advantage of the specifically designed
essential for the evaluation of drug responses mechanical/electrical properties of non-living (inert)
in many tissues, such as the multiple-layered barrier parts and connect these parts firmly with the
function of thevascularizedskinorthelargeforce- biofabricated tissues so that the chemical, mechanical,
to-displacement transduction functionofskeletal and electrical stimulation can be correctly applied to
muscle/cardiactissue. test specific tissue functions.
First, the multiple-layered barrier functions to In terms of skin fabrication, we have demonstrated
control the transdermal delivery of external-use drugs the potential of our biohybrid approach for the
through the epidermis of the applied location all the reconstruction of the multiple-layered barrier func-
way to the capillary vessels beneath the dermis. For tion of in vitro skin equivalents. These systems aim to
example, the evaluation of cosmetics includes toxicity- create an in vitro model for the transdermal delivery of
induced diseases and requires measuring the amount external-use drugs/cosmetics. Using these tools, we
of drug-containing toxic compounds that penetrate have fabricated skin tissues in 3D-printed tissue
17
Biofabrication 12 (2020) 022002 W Sun et al
Figure 6. A skin equivalent integrated with perfusable vascular channels for drug permeability testing. (a), (b) A schematic and
photograph of the experimental setup. (c), (d) Amounts of caffeine permeating the medium beneath the skin equivalents (medium A,
B). Copyright: reproduced with permission from [49], copyright 2017 Elsevier Ltd.
housing with sacrificial nylon wires threaded through bioprinting methods to create more accurate cell/
bulky tissues to create perfusable vascular networks ECM distribution.
(figure 6) [49, 50]. The detailed fabrication process is In terms of muscle fabrication, we reconstructed
as follows. First, a piece of skin equivalent is fabricated the large force-to-displacement transduction function
by pouring a fibroblast/collagen mixture into a 3D- of biohybrid skeletal muscle/cardiac tissue by incor-
printed housing followed by the subsequent seeding of porating anchoring structures. In detail, we 3D-
keratinocytes; after the formation of the skin equiva- printed pillar arrays (e.g. with electrodes patterned
lent, the fabricated dermis can firmly anchor to the using photolithography)using SLA and microma-
side wall of a 3D-printed housing, even after drastic chining. Then, cells were dispensed onto the prefabri-
contraction of the dermis tissue. Next, a lumen is cated 3D parts; upon culture, cells condensed and
formed by pulling out the sacrificial nylon wire grabbed the anchoring structures, thus forming tight
followed by the subsequent seeding of HUVECs. This mechanical connections between a non-living (skeletal
fabricated skin equivalent could withstand pressures
construct) and living parts (muscle tissue). Using this
required for sample perfusion during drug screening.
strategy, we have successfully fabricated muscular
To investigate the influence of vascular perfusion on
tissues, and were able to transform muscular contrac-
percutaneous absorption, we have monitored the
tion to mechanical motion for the modelling of
permeation of test molecules, caffeine and ISDN
muscular systems (figure 7) [51–53]. To demonstrate
(isosorbide dinitrate), through the skin equivalent
during the perfusion of Dulbecco’s Modified Eagle drug reactivity, we applied isoproterenol and propra-
Medium (DMEM) in the vascular channels; the nolol to the biofabricated tissue, and we were able to
normalized permeated amount of ISDN was three- to detect an increase inpeak-to-peak (p–p) contractile
fourfold higher than that of caffeine [49]. The differ- force after the addition of isoproterenol, and a
ences in permeability between caffeine and ISDN, decrease in p–p contractile forceafter the addition of
which are consistent with previous studies, have propranolol [51]. In the future, we will attempt to
shown the applicability of our 3D-printed hybrid skin extendour biohybridstrategy to multiprinthead bio-
as a promising in vitro model for skin disease therapy printers [54] to produce the biohybrid skeletal mus-
development. In the future, we plan to replace the cle/cardiac tissue with high-throughput in the future.
moulding methods previously adopted for dermis/ In addition, we will attempt to incorporate nano-scale
epidermis fabrication with robotic-assisted details into the 3D-printed parts using high-resolution
18
Biofabrication 12 (2020) 022002 W Sun et al
Figure 7. A schematic illustration (top) of the contractile force measurements of the human induced pluripotent stem cell-derived
cardiomyocytes (hiPS-CM) fibres. The contractile force was estimated from the cantilever deformation. The graphs (bottom) show
the contractile frequency of the hiPS-CM fibres and clumps 30 min after the addition or removal of isoproterenol and propranolol.
Copyright: reproduced with permission from [51], published by The Royal Society of Chemistry.
3D printing technology so that the biohybrid micro- biohybrid tissues to which chemical, mechanical, or
tissuescan bettermodel the in vivo muscle tissue [55]. electrical stimulation can be appliedto create disease
models of single/multi tissue systems. Our strategy
7.4. Concluding. Bioprinting is a field that is coming- has the potential to be fully automated, and therefore
of-age, with the early achievements in the fabrication can be adapted for the mass production of functional
of cellular constructs, with tissue and disease model biofabricated tissues for disease study.
value. To further transform the technology for disease
modelling, challenges—such as the establishment of
perfusable multilayered skin barrier function and the
realization of the large force-to-displacement Acknowledgments
transduction function of muscular tissue—have yet to We would like to thank all members of the BioHybrid
be met but appear within reach. We propose to System Lab, The University of Tokyo for their help
overcome these challenges by creating 3D-printed and support.
19
Biofabrication 12 (2020) 022002 W Sun et al
20
Biofabrication 12 (2020) 022002 W Sun et al
Figure 8. Multimaterial bioprinting of 3D constructs. (A), (B) Bioprinting of dual‐ and triple‐layered cuboid blocks. (C)–(E)
Bioprinting of blood‐vessel‐like structures (transverse plane) containing dual, triple, and quadruple materials. (F) Bioprinting of a
pyramid containing seven layers of different bioinks. (G), (H) Bioprinting of three‐ and ten‐layered blocks with continuous segments
of seven different bioinks. (I) Bioprinting of human organ‐like constructs from multiple bioinks, including brain, lung, heart, liver,
kidneys, pancreas, stomach, small/large intestines, bladder, and prostate. The organ‐like constructs were individually printed,
photographed, and stitched together in the same image at relative locations as those in the human body. (J)–(N) A side view of selected
organ‐like constructs indicating their 3D nature: (J) brain, (K) lung vasculature, (L) kidney, (M) left atrium of heart, (N) bladder/
prostate. The organ‐like structures were not printed to scale to each other. From Liu et al 2017 [60], ©2016 John Willey and Sons.
Figure 9. An integrated, automated multiorgan-on-a-chip platform with sensing capability. (A) A schematic of a biomimetic human
heart- and liver-on-a-chip. (B) An integrated primary hepatic and iPSC-cardiac dual-organoid platform, live/dead staining of the
hepatic organoids after 0, 5, 10 mM acetaminophen (APAP) treatment for 120 h. (C) Normalized cell viability in the presence of APAP
from day 1 to day 5. Modified from Zhang et al 2017 [63].
testing. Additionally, multimaterial bioinks have been micromirror device (DMD) bioprinting combined
developed with the ability to support a variety of cell with computed tomography has also yielded
types and spatially segregate formation of distinct promising results in vascular fabrication. These efforts
tissue structures [60]. However, more multimaterials should be pursued further to develop high-
like these are needed to facilitate printing a wider throughput fabrication methods with the ability to
variety of cells. Many efforts have also been made to bioprint thick (>1 mm), vascularized, heterogeneous
bioprint blood vasculature. Coaxial bioprinting has tissues for implementation into organ-on-a-chip
been developed for the fabrication of tubular systems. Recently, Bhise et al fabricated a liver-on-a-
constructs to recreate vessel structures. Recently, Pi chip platform with a bioprinted dot array of hepatic
et al showed one-step fabrication of multilayered spheroids encapsulated in GelMA hydrogel. They
tubular tissues with cellular heterogeneity using a monitored hepatic function for one month, and used
multichannel coaxial extrusion system [64]. Digital the platform to evaluate the toxicity of acetaminophen
21
Biofabrication 12 (2020) 022002 W Sun et al
on liver cells [65]. In another study, Skardal et al concentrated on the engineering of thick tissues and
bioprinted liver, heart, and lung organoids to develop the integration of vasculature. Furthermore, the use of
a multiorgan-on-a-chip platform to investigate the human stem cells demands improved matrices to
interactions between organs and the individual and support their growth and differentiation. In the future,
collective response towards drugs and toxins [57]. it may be possible to develop in vivo-like organs in vitro
Furthermore, they developed biosensors to provide to revolutionize modern medicine and healthcare by
real-time data acquisition on the microfluidic developing organ-on-a-chip platforms used in
platform. personalized drug screening, drug development, and
improving drug safety.
8.4. Concluding Remarks. Current development in
3D bioprinting has focused on the fabrication of
tissues with greater complexity and a better ability to Acknowledgments
mimic in vivo behaviour. To achieve increased ex vivo The authors acknowledge Peyton Tebon for helpful
similarity, size, and complexity, efforts have been comments.
22
Biofabrication 12 (2020) 022002 W Sun et al
9. Biomanufacturing of multicellular order to gain the desired form and function. In the
engineered living systems extreme, the growth of organoids from aggregates of
pluripotent cells requires no printing at all; the cells do
Roger D Kamm the work themselves, developing the minute structures
Massachusetts Institute of Technology characteristic of a particular organ through their
inherent, ‘hard-wired’ programs. Moreover, these
9.1. Status. Over the last decade, several key same intrinsic competencies enable the ‘manufactured
advances have been made with important implications product’ not only to self-assemble, but also to self-
for the development of multicellular engineered living repair, adapt to changing conditions, and even poten-
systems (M-CELS). First, the Yamanaka group in tially to self-replicate.
Japan demonstrated that induced pluripotent cells
could be produced from human dermal fibroblasts 9.2. Current and future challenges. To develop
[66] using a newly developed protocol. While the M-CELS that meet the rigorous requirements of
experimental procedures have since been refined and industrial application, or even the need for
extended, it is now widely accepted that a pluripotent repeatability in the research setting, a new approach is
cell population can be obtained from fibroblasts of any needed in biofabrication. Driven by the recognition
subject. Second, in 2011, the first reports appeared that the manufacture of biological systems is
describing the methods that could be employed to fundamentally different from that of abiotic systems,
produce an organ-like cell assembly from a cluster of entirely new approaches to design, manufacture and
pluripotent cells to produce an optic cup [67]. Many quality control are needed. These differences
others have appeared since, notably organoids for the represent, at the same time, barriers to progress and
brain [68] and hindgut [69]. And lastly, the continued opportunities. One barrier is that much of the
development of microfluidic technology based on soft developed practice based on non-biological systems—
lithographic methods, has fostered the growth of including virtually all the manufactured items now
microphysiological systems; M-CELS that exhibit produced—is largely inappropriate for M-CELS. All
some aspects of organ form and function have current design and manufacturing principles are based
demonstrated potential for disease models, and show on the fact that the interactions between the various
components of a system can be predicted based on
promise for drug screening (figure 10). Numerous
known physical principles. In biological systems, the
organ systems have now been reported in the literature
components (cells and molecules) interact in ways that
and the number continues to grow, as does their
we have still only begun to appreciate. Take, for
ability to replicate real human organ function. The
example, the ability of a collection of muscle cells to
combination of these three technologies has led to the
self-assemble into a muscle bundle and produce
recent optimism among many, that human organ
collective contractions [71], or the ability of a
systems can be produced with sufficient realism and
population of endothelial cells to self-organize into a
consistency that opens the door to various
3D network with perfusable lumens [72]. While even
applications, but importantly, as a new and valuable
these relatively primitive processes remain beyond the
tool for the pharma and biotech industries. Indeed, reach of our understanding, they also present an
most, if not all, major pharma companies now have opportunity. In creating a muscle, one need not place
vigorous activities in these areas. each myocyte in the precise location desired in the
At present, there are essentially two methods used final muscle ‘actuator’, but simply place them in close
to fabricate M-CELS [70]. In one method—‘top-down proximity that enables them to interact naturally and
engineering’—cells are seeded onto or into substrates, to self-organize. Numerous examples can be found in
in precisely the format needed to perform their which such self-assembly occurs and makes possible
function. Simple monolayers fall into this category, as the creation of organ-like systems. One enormous
well as cells widely dispersed in a natural or synthetic challenge is to establish the fundamental
matrix, that are not required to interact. The second understanding necessary to take a brain organoid, for
method takes advantage of the natural ability of cells to example, and induce it to grow an appropriate
differentiate and self-organize; one might call this vasculature, or to introduce functional inputs and
‘emergent engineering’. The first of these follows well- outputs in order to take advantage of the brain’s
established procedures, and is well suited to bioprint- unique information processing capabilities.
ing. The latter is much less established or understood, Other features of natural biological systems—self-
and the applicability of bioprinting depends on the repair, adaptation, even self-replication—all pose
type of system being fabricated. Issues of cell density, opportunities, if advanced through a reasoned
cell viability, matrix composition and density, and approach, keeping in mind the potentially important
variety of cell types needed all come into play, and in ethical implications of such capabilities.
the end, one needs to rely on the intrinsic capability of
the cells to modulate their phenotype, through inter- 9.3. Advances in science and technology to meet
actions with their neighbouring cells and matrix, in challenges. Bioprinting represents but one of many
23
Biofabrication 12 (2020) 022002 W Sun et al
Figure 10. A schematic showing the process for producing M-CELS for various applications.
approaches that, when further developed, can play an 9.4. Concluding remarks. There is little doubt that
important role in the manufacture of M-CELS. bioprinting will prove to be a useful tool in the
Drawing upon the self-organizing capabilities of living fabrication of M-CELS, but its range of applicability
cells, it has already proven sufficient in a number of will depend on several factors and the ability to
studies, when growing a particular biological surmount the challenges mentioned above. There will
component, to place the various cells in sufficiently need to be a fundamental change in the way that we
close proximity to each other in an appropriate matrix address the fabrication of complex biological systems,
material or on a suitable substrate and let them ‘do and the ability for self-assembly needs to be embraced
their own thing.’ But tissues are dense cellular and understood. Biological variability also needs to be
structures, and current bioprinting methods are recognized and reduced to the extent possible. Finally,
limited in their ability to print at the high cell
much work is needed before the full potential of
concentrations needed, or with the spatial resolution
organoid systems can be fully realized. And when it is,
necessary for the smallest biological structures [73]. In
the role for bioprinting needs to be re-examined.
going to finer and finer resolution, the shear forces on
Perhaps it comes in when we start to address the need
the cells being printed will also increase, raising
concerns about the potential for cell damage, or at to interact with or interrogate the organ, but many
least activation due to the mechanical stimulus. questions remain, and the field is currently wide open
Perhaps the more important need is for a reliable and ripe for important advances.
computational approach to predict the structure and
performance of the resultant system. While engineered
systems are relatively straightforward, especially those Acknowledgments
containing simple structures such as monolayers, more Support from the National Science Foundation for the
complex tissue arrangements mandate a more rigorous Science and Technology Center on Emergent Beha-
and comprehensive understanding, which will subse- viors of Integrated Cellular Systems (CBET- 0939511)
quently lead to modelling capabilities. is greatly appreciated.
24
Biofabrication 12 (2020) 022002 W Sun et al
10.1. Status. Three-dimensional bioprinting could be Figure 11. An extrusion-type space 3D bioprinter ‘Allevi
defined as a robotic biofabrication of 3D functional ZeroG’ (according to Allevi, USA with permission).
tissue and organ constructs from living cells and
biomaterials according to a digital model. Several
research groups and companies in the USA, European under the conditions of microgravity in space allows
Union, Russia, and China are already actively preparing the use of more biocompatible and usually less viscous
the necessary research infrastructure and biofabrication bioink, thus enabling bioprinting of geometrically
devices, such as bioassemblers and bioprinters, for 3D more complex tissues and organ constructs with large
bioprinting in space. Bioassemblers could be defined as empty space, channels, and voids. Therefore, extru-
devices that enable the bioassembly of 3D tissue and sion-based bioprinting under the conditions of micro-
organ constructs which do not require traditional layer- gravity in space have certain advantages compared
by-layer additive biofabrication, and could be based on with bioprinting under the conditions of gravity on
novel principles of formative biofabrication (see below) Earth. Bioprinted in space tissue models can be used to
and programmed self-assembly.In this context several study the physiology of tissues and organs exposed to
logical questions are arising: space conditions, such as microgravity and radiation.
This will be important in understanding the biological
(i) What is a rationale for performing bioprinting effects of the space environment for long-term
experiments in space? manned missions [74–80].
(ii) What are the potential advantages of bioprinting 10.2. Current and future challenges. Magnetic
in space compared with more traditional tissue levitation is another emerging space bioprinting
engineering approaches? technology. The American company n3D
(iii) How 3D bioprinting in space will advance biofab- Biosciences, Inc. already performed magnetic
rication and bioprinting technologies. levitational experiments at The International Space
Station in 2017. One of the objectives of the project
(iv) How bioprinting technology could be used to ‘Magnetic 3D Cell Culture for Biological Research in
enable further human deep space exploration, Microgravity’ was to use magnetized cells and tools to
including establishing long-term sustainable make it easier to handle cells and cultures, to improve
human planetary settlements. the reproducibility of experiments, and to determine
whether biological events in these cultures result from
Extrusion-based 3D bioprinting is the most popu- gravity or substrate attachment. However, magnetic
lar and broadly used variant of bioprinting technology levitational experiments have been performed
on Earth. Thus, it is not a big surprise that the first 3D without employing the specially designed magnetic 3D
bioprinter tested under the conditions of microgravity bioprinter. The Russian company 3D Bioprinting
in space during a parabolic rocket fly was an extrusion- Solutions plans to use a label-free magnetic levitational
type bioprinter. Several USA companies are actively bioassembly of tissue engineered constructs or so-called
working on the development of certified space 3D ‘formative biofabrication’,where a magnetic field will
bioprinters of the extrusion type for performing be used as a sort of temporal support or ‘scaffold’. A
bioprinting experiments at The International Space magnetic space bioprinter ‘Organ.aut’has been already
Station (figure 11). The main challenge of extrusion- designed, produced, and certified for performing
based 3D bioprinting using bioinks is finding the bioprinting experiments at The Russian segment of The
optimal conditions between the printability and International Space Station in October 2018 (figure 12).
fidelity of bioprinted constructs and their biocompat- Implementation of magnetic levitation under the
ibility. Viscous bioinks have bioprintability with a high conditions of gravity on Earth requires using relatively
level of fidelity, but their biocompatibility and permis- toxic paramagnetic medium, including, for example,
siveness for post-printed sprouting angiogenesis are gadolinium. Microgravity conditions in space will
usually compromised. Three-dimensional bioprinting enable magnetic levitation using a 100 times
25
Biofabrication 12 (2020) 022002 W Sun et al
26
Biofabrication 12 (2020) 022002 W Sun et al
27
Biofabrication 12 (2020) 022002 W Sun et al
28
Biofabrication 12 (2020) 022002 W Sun et al
Figure 13. Classification of bioprinting technologies (adapted with permission from [81]).
demonstrated the effective coupling of EBB and demonstrated acoustophoretic printing technology
photo‐crosslinking. The scalability problem of cell (see figure 14(D)). This new technology enables
transfer‐based approaches (e.g. LIFT) has been miti- dispensing of droplets of high viscous inks (with
gated by the work performed by Huang and co‐ viscosities up to 25 000 mPa·s) or yield stress fluids
workers [86], where 3D volumetric tubular constructs, (τ0>50 Pa)) [89]. Further, the Lewis laboratory has
as shown in figure 14(C), were bioprinted by deposit- demonstrated the application of acoustophoretic
ing alginate jets into a crosslinker vat with a levelling printing technology in bioprinting of an MSC‐laden
mechanism. It would be useful if further advance- 5 mg ml−1 collagen solution. Such an advancement
ments were performed for other bioinks, particularly has the potential to print droplets of other viscous
biologically useful bioinks (e.g. collagen) that crosslink bioinks, which is not quite feasible with existing DBB
slowly. On the other hand, the mechanical and technologies.
structural integrity of tissue constructs fabricated via
DBB has been ensured by integrating electrospinning 11.4. Concluding remarks. Although great progress has
[87], where bioink droplets were deposited onto been made in bioprinting technologies over the last
electrospun fibres. A similar arrangement has been decade, each modality possesses its own limitations,
utilized in EBB of low viscous hydrogels or decellular- including, but not limited to, process resolution,
ized ECM components [88] with the integration of scalability, and availability of compatible bioinks;
melt‐extruded polymeric frames. One of the contri- however, to date, the advances of each method seem to
buting factors to the scalability problem is the limited complement the shortcomings of other methods. Thus,
viscosity of bioinks that current DBB technologies can to fill in the current technological gaps, it is likely that in
tolerate. In this regard, the Lewis laboratory recently the future technologies will encompass and utilize
29
Biofabrication 12 (2020) 022002 W Sun et al
Figure 14. (A) The FRESH bioprinting approach enabling plotting of bioink into a gelatin support bath, which acts like a Bingham
plastic (solid at 22 °C and liquid at 37 °C) (adapted from [85]). (B) An in situ crosslink of photocrosslinkable gels facilitating
bioprinting of high-fidelity constructs (adapted with permission from [17]). (C) The LIFT process with a support bath of crosslinking
solution facilitates the bioprinting of branched vascular constructs (adapted with permission from [86]). (D) Acoustophoretic printing
using sound waves to facilitate the deposition of droplets (adapted from [89]).
30
Biofabrication 12 (2020) 022002 W Sun et al
31
Biofabrication 12 (2020) 022002 W Sun et al
induced pluripotent stem cells in suspension culture [54] Lind J U et al 2017 Instrumented cardiac microphysiological
Bioprocess. Biosyst. Eng. 40 123–31 devices via multimaterial three-dimensional printing Nat.
[36] Shinohara M, Choi H-J, Ibuki M, Yabe S G, Okochi H, Mater. 16 303–8
MIyajima A and Sakai Y Endodermal differentiation of human [55] Gullo M R, Takeuchi S and Paul O 2017 Multicellular
induced pluripotent stem cells using simple dialysis culture biohybrid materials: probing the interplay of cells of different
system in suspension culture Regen. Ther. 12 14–9 types precisely positioned and constrained on 3D wireframe-
[37] Jang J, Park J Y, Gao G and Cho D-W 2018 Biomaterials-based like microstructures Adv. Healthc. Mater. 6 201601053
3D cell printing for next-generation therapeutics and [56] Selimović Š, Dokmeci M R and Khademhosseini A 2013
diagnostics Biomaterials 156 88–106 Organs-on-a-chip for drug discovery Curr. Opin. Pharmacol.
[38] Jang J, Park H-J, Kim S-W, Kim H, Park J Y, Na S J, Kim H J, 13 829–33
Park M N, Choi S H and Park S H 2017 3D printed complex tissue [57] Skardal A et al 2017 Multi-tissue interactions in an integrated
construct using stem cell-laden decellularized extracellular matrix three-tissue organ-on-a-chip platform Sci. Rep. 7 8837
bioinks for cardiac repair Biomaterials 112 264–74 [58] Zhang Y S et al 2016 Bioprinting 3D microfibrous scaffolds for
[39] Kim B S, Kwon Y W, Kong J-S, Park G T, Gao G, Han W, engineering endothelialized myocardium and heart-on-a-chip
Kim M-B, Lee H, Kim J H and Cho D-W 2018 3D cell printing Biomaterials 110 45–59
of in vitro stabilized skin model and in vivo pre-vascularized [59] Ashammakhi N, Ahadian S, Zengjie F, Suthiwanich K,
skin patch using tissue-specific extracellular matrix bioink: a Lorestani F, Orive G, Ostrovidov S and Khademhosseini A
step towards advanced skin tissue engineering Biomaterials 168 2018 Advances and future perspectives in 4D bioprinting
38–53 Biotechnol. J. 13 1800148
[40] Arakawa C K, Badeau B A, Zheng Y and DeForest C A 2017 [60] Liu W et al 2017 Rapid continuous multimaterial extrusion
Multicellular vascularized engineered tissues through bioprinting Adv. Mater. 29 1604630
user‐programmable biomaterial photodegradation Adv. [61] Zhang Y S and Khademhosseini A 2015 Seeking the right
Mater. 29 1703156 context for evaluating nanomedicine: from tissue models in
[41] Gao G, Lee J H, Jang J, Lee D H, Kong J S, Kim B S, Choi Y J, petri dishes to microfluidic organs-on-a-chip Nanomedicine
Jang W B, Hong Y J and Kwon S M 2017 Tissue engineering: 10 685–8
tissue engineered bio‐blood‐vessels constructed using a tissue‐ [62] Schnitzler A C et al 2016 Bioprocessing of human
specific bioink and 3D coaxial cell printing technique: a novel mesenchymal stem/stromal cells for therapeuthic use: current
therapy for ischemic disease (Adv. Funct. Mater. 33/2017) technologies and challenges Biochem. Eng. J. 108 3
Adv. Funct. Mater. 27 [63] Zhang Y S et al 2017 Multisensor-integrated organs-on-
[42] Jakab K, Norotte C, Marga F, Murphy K, chips platform for automated and continual in situ
Vunjak-Novakovic G and Forgacs G 2010 Tissue engineering monitoring of organoid behaviors Proc. Natl Acad. Sci. USA
by self-assembly and bio-printing of living cells Biofabrication 114 E2293–302
2 022001 [64] Pi Q et al 2018 Digitally tunable microfluidic bioprinting of
[43] Das S, Kim S-W, Choi Y-J, Lee S, Lee S-H, Kong J-S, Park H-J, multilayered cannular tissues Adv. Mater. 30 1706913
Cho D-W and Jang J 2019 Decellularized extracellular matrix [65] Bhise N S et al 2016 A bioprinted liver-on-a-chip for drug
bioinks and the external stimuli to enhance cardiac tissue screening applications Trends Biotechnol. 34 681
development in vitro Acta Biomater. 95 188–200 [66] Takahashi K and Yamanaka S 2006 Induction of pluripotent
[44] Ruan J-L, Tulloch N L, Razumova M V, Saiget M, Muskheli V, stem cells from mouse embryonic and adult fibroblast cultures
Pabon L, Reinecke H, Regnier M and Murry C E 2016 by defined factors Cell 126 663–76
Mechanical stress conditioning and electrical stimulation [67] Hasegawa Y, Takata N, Okuda S, Kawada M, Eiraku M and
promote contractility and force maturation of induced Sasai Y 2016 Emergence of dorsal-ventral polarity in ESC-
pluripotent stem cell-derived human cardiac tissue Circulation derived retinal tissue Development (Cambridge, England) 143
134 1557–67 3895–906
[45] Pati F, Jang J, Ha D-H, Kim S W, Rhie J-W, Shim J-H, [68] Lancaster M A, Renner M, Martin C-A, Wenzel D, Bicknell L S,
Kim D-H and Cho D-W 2014 Printing three-dimensional Hurles M E and Knoblich J A 2013 Cerebral organoids model
tissue analogues with decellularized extracellular matrix bioink human brain development and microcephaly Nature 501
Nat. Commun. 5 3935 373–9
[46] Lee H, Han W, Kim H, Ha D-H, Jang J, Kim B S and Cho D-W [69] Spence J R, Mayhew C N, Rankin S A, Kuhar M F, Vallance J E,
2017 Development of liver decellularized extracellular matrix Tolle K and Wells J M 2011 Directed differentiation of human
bioink for three-dimensional cell printing-based liver tissue pluripotent stem cells into intestinal tissue in vitro Nature 470
engineering Biomacromolecules 18 1229–37 105–9
[47] Ma X, Liu J, Zhu W, Tang M, Lawrence N, Yu C, Gou M and [70] Kamm R D and Zaman M H 2018 The promise of multicellular
Chen S 2018 3D bioprinting of functional tissue models for engineered living systems APL Bioengineering 2 040901
personalized drug screening and in vitro disease modeling Adv. [71] Raman R, Cvetkovic C and Bashir R 2017 A modular approach
Drug Deliv. Rev. 132 235–51 to the design, fabrication, and characterization of muscle-
[48] Bell E, Ehrlich H P, Buttle D J and Nakatsuji T 1981 Living powered biological machines Nat. Protoc. 12 519–33
tissue formed in vitro and accepted as skin-equivalent tissue of [72] Lee S, Ko J, Park D, Lee S-R, Chung M, Lee Y and Jeon N L 2018
full thickness Science 211 1052–4 Microfluidic-based vascularized microphysiological systems
[49] Mori N, Morimoto Y and Takeuchi S 2017 Skin integrated with Lab Chip 18 2686–709
perfusable vascular channels on a chip Biomaterials 116 48–56 [73] Blaeser A, Duarte Campos D F, Puster U, Richtering W,
[50] Mori N, Morimoto Y and Takeuchi S 2018 Perfusable and Stevens M M and Fischer H 2016 Controlling shear stress in 3D
stretchable 3D culture system for skin-equivalent bioprinting is a key factor to balance printing resolution and
Biofabrication 11 011001 stem cell integrity Adv. Healthcare Mater. 5 326–33
[51] Morimoto Y, Mori S, Sakai F and Takeuchi S 2016 Human [74] Ghidini T 2018 Regenerative medicine and 3D bioprinting for
induced pluripotent stem cell-derived fiber-shaped cardiac human space exploration and planet colonisation J. Thorac.
tissue on a chip Lab Chip 16 2295–301 Dis. 10 S2363–75
[52] Shima A, Morimoto Y, Sweeney H L and Takeuchi S 2018 [75] Rothschild L J 2016 Synthetic biology meets bioprinting:
Three-dimensional contractile muscle tissue consisting of enabling technologies for humans on Mars (and Earth)
human skeletal myocyte cell line Exp. Cell. Res. 370 168–73 Biochem. Soc. Trans. 44 1158–64
[53] Morimoto Y, Onoe H and Takeuchi S 2018 Biohybrid robot [76] Becker J L and Souza G R 2013 Using space-based
powered by an antagonistic pair of skeletal muscle tissues Sci. investigations to inform cancer research on Earth Nat. Rev.
Robot. 3 eaat4440 Cancer 13 315–27
32
Biofabrication 12 (2020) 022002 W Sun et al
[77] Freed L E, Langer R, Martin I, Pellis N R and [84] Odde D J and Renn M J 1999 Laser‐guided direct writing for
Vunjak-Novakovic G 1997 Tissue engineering of cartilage in applications in biotechnology Trends Biotechnol. 17 385–9
space Proc. Natl Acad. Sci. USA 94 13885–90 [85] Hinton T J, Jallerat Q, Palchesko R N, Park J H, Grodzicki M S,
[78] Unsworth B R and Lelkes P I 1998 Growing tissues in Shue H ‐ J, Ramadan M H, Hudson A R and Feinberg A W 2015
microgravity Nat. Med. 4 901–7 Three‐dimensional printing of complex biological structures
[79] Grimm D, Wehland M, Pietsch J, Aleshcheva G, Wise P, by freeform reversible embedding of suspended hydrogels Sci.
van Loon J, Ulbrich C, Magnusson N E, Infanger M and Bauer J Adv. 1 e1500758
2014 Growing tissues in real and simulated microgravity: new [86] Xiong R, Zhang Z, Chai W, Huang Y and Chrisey D B 2015
methods for tissue engineering Tissue Eng. Part B Rev. 20 Freeform drop‐on‐demand laser printing of 3D alginate and
555–66 cellular constructs Biofabrication 7 045011
[80] Souza G R et al Three-dimensional tissue culture based [87] Xu T, Binder K W, Albanna M Z, Dice D, Zhao W, Yoo J J and
on magnetic cell levitation Nat. Nanotechnol. 2010 5 Atala A 2013 Hybrid printing of mechanically and biologically
291–6 improved constructs for cartilage tissue engineering
[81] Ozbolat I T 2016 3D Bioprinting: Fundamentals, Principles and applications Biofabrication 5 015001
Applications (Amsterdam: Elsevier) [88] Pati F, Jang J, Ha D ‐ H, Won Kim S, Rhie J ‐ W, Shim J ‐ H,
[82] Ozbolat I T and Hospodiuk M 2016 Current advances and Kim D ‐ H and Cho D ‐ W 2014 Printing three‐ dimensional
future perspectives in extrusion‐ based bioprinting tissue analogues with decellularized extracellular matrix bioink
Biomaterials 76 321–43 Nat. Commun. 5 4935
[83] Gudapati H, Dey M and Ozbolat I 2016 A comprehensive [89] Foresti D, Kroll K T, Amissah R, Sillani F, Homan K A,
review on droplet‐based bioprinting: past, present and future Poulikakos D and Lewis J A 2018 Acoustophoretic printing Sci.
Biomaterials 102 20–42 Adv. 4 eaat1659
33